Donald Trump's electoral victory has unexpectedly led to market gains, with the S&P 500 rising 5% shortly after the election. However, not all sectors have prospered, particularly pharmaceuticals.
Pfizer, a prominent player in the pharmaceutical industry, may face significant scrutiny under the Trump administration, potentially endangering its stock performance in the coming years.
Despite recent turmoil, Pfizer has maintained a trajectory of strong dividend growth, showcasing a 15-year history of increasing payouts and solid sales from its diversified drug portfolio.
The long-term outlook for Pfizer’s stock remains cautiously optimistic, as its extensive pipeline of drugs in clinical trials may provide new revenue streams amid current pressures.
Collection
[
|
...
]